@MickeyMantle536 Sure but wasn't the existing $30+ million sufficient to take us to some clinical programs to inflection points (and therefore less dilutive raises) in the not so distant future? Why raise now at a discount to the already low price, I guess is the question, and with the low option price to boot.
